Initiator Pharma A/S
STO: INIT.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Claus Elsborg Olesen
- Employees
- 2
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2017
- Market cap
- SEK 230.0M
- Website
- https://www.initiatorpharma.com
Loading INIT…
Loading profile data…Frequently asked questions about INIT
What does Initiator Pharma A/S (INIT.ST) do?
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021...
Where does INIT.ST trade?
Initiator Pharma A/S (INIT.ST) trades on the Stockholm Stock Exchange.
What sector is INIT.ST in?
Initiator Pharma A/S (INIT.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Initiator Pharma A/S?
Claus Elsborg Olesen is the chief executive officer of Initiator Pharma A/S (INIT.ST).
Where is Initiator Pharma A/S headquartered?
Initiator Pharma A/S is headquartered in Denmark.
Does INIT.ST pay a dividend?
Initiator Pharma A/S (INIT.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INIT.ST go public?
Initiator Pharma A/S (INIT.ST) completed its initial public offering in 2017.